Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

The dual SRC/ABL1 tyrosine kinase inhibitor bosutinib is indicated for adults with Ph+ chronic myeloid leukaemia (CML) resistant/intolerant to prior therapy. This analysis of an ongoing phase 1/2 study (NCT00261846) assessed effects of baseline patient characteristics on long‐term efficacy and safet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Haematol
Päätekijät: Brümmendorf, Tim H., Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Kim, Dong‐Wook, Schafhausen, Philippe, Conlan, Maureen G., Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Gambacorti‐Passerini, Carlo, Lipton, Jeff H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2015
Aiheet:
Haematological Malignancy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737299/
https://ncbi.nlm.nih.gov/pubmed/26537529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13801
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia